FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1504059837> ?p ?o ?g. }

• W1504059837 endingPage "1254" @default.
• W1504059837 startingPage "1240" @default.
• W1504059837 abstract "To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of odanacatib (ODN), a cathepsin K inhibitor, in humans.Two double-blind, randomized, placebo-controlled, single oral dose studies were performed with ODN (2-600 mg) in 44 healthy volunteers (36 men and eight postmenopausal women).Adverse experiences (AEs) with single doses of ODN were transient and mild to moderate, with the exception of one severe AE of gastroenteritis. Headache was the most frequent AE. After absorption of ODN (initial peak concentrations 4-6 h postdose), plasma concentrations exhibited a monophasic decline, with an apparent terminal half-life of ∼40-80 h. The area under the curve0-24 hours (AUC(0-24 h)), concentration at 24 hours (C(24 h)) and maximum concentration (C(max,overal)) increased in a less than dose-proportional manner from 2 to 600 mg. Administration of ODN with a high-fat meal led to ∼100% increases in AUC(0-24 h), C(max,day1), C(max,overall) and C(24 h) relative to the fasted state, while administration with a low-fat meal led to a ∼30% increase in those parameters. Reduction of biomarkers of bone resorption, the C- and N-telopeptides of cross-links of type I collagen, (CTx and NTx, respectively), was noted at 24 h for doses ≥5 mg and at 168 h postdose for ≥10 mg. In postmenopausal women administered 50 mg ODN, reductions in serum CTx of -66% and urine NTx/creatinine (uNTx/Cr) of -51% relative to placebo were observed at 24 h. At 168 h, reductions in serum CTx (-70%) and uNTx/Cr (-78%) were observed relative to baseline. Pharmacokinetic/pharmacodynamic modeling characterized the ODN concentration/uNTx/Cr relation, with a modeled EC50 value of 43.8 nM and ∼80% maximal reduction.Odanacatib was well tolerated and has a pharmacokinetic and pharmacodynamic profile suitable for once weekly dosing." @default.
• W1504059837 created "2016-06-24" @default.
• W1504059837 creator A5011021512 @default.
• W1504059837 creator A5012368560 @default.
• W1504059837 creator A5020043851 @default.
• W1504059837 creator A5024807342 @default.
• W1504059837 creator A5026975469 @default.
• W1504059837 creator A5029825407 @default.
• W1504059837 creator A5033319328 @default.
• W1504059837 creator A5038185249 @default.
• W1504059837 creator A5040155351 @default.
• W1504059837 creator A5044409463 @default.
• W1504059837 creator A5045458724 @default.
• W1504059837 creator A5061427649 @default.
• W1504059837 creator A5061747115 @default.
• W1504059837 creator A5065379353 @default.
• W1504059837 creator A5069747518 @default.
• W1504059837 date "2013-04-08" @default.
• W1504059837 modified "2023-09-23" @default.
• W1504059837 title "Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers" @default.
• W1504059837 cites W104095340 @default.
• W1504059837 cites W1963957178 @default.
• W1504059837 cites W1968024679 @default.
• W1504059837 cites W1972962589 @default.
• W1504059837 cites W1987556207 @default.
• W1504059837 cites W1989560280 @default.
• W1504059837 cites W1998122353 @default.
• W1504059837 cites W2010654750 @default.
• W1504059837 cites W2025062557 @default.
• W1504059837 cites W2040156285 @default.
• W1504059837 cites W2050801935 @default.
• W1504059837 cites W2055819749 @default.
• W1504059837 cites W2065305027 @default.
• W1504059837 cites W2068503643 @default.
• W1504059837 cites W2072519450 @default.
• W1504059837 cites W2091713669 @default.
• W1504059837 cites W2093204833 @default.
• W1504059837 cites W2100282191 @default.
• W1504059837 cites W2103822828 @default.
• W1504059837 cites W2120690710 @default.
• W1504059837 cites W2144207870 @default.
• W1504059837 cites W2159469066 @default.
• W1504059837 cites W2160295774 @default.
• W1504059837 cites W2163350629 @default.
• W1504059837 cites W2233138207 @default.
• W1504059837 cites W2334629346 @default.
• W1504059837 cites W4250407548 @default.
• W1504059837 doi "https://doi.org/10.1111/j.1365-2125.2012.04471.x" @default.
• W1504059837 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3635595" @default.
• W1504059837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23013236" @default.
• W1504059837 hasPublicationYear "2013" @default.
• W1504059837 type Work @default.
• W1504059837 sameAs 1504059837 @default.
• W1504059837 citedByCount "65" @default.
• W1504059837 countsByYear W15040598372013 @default.
• W1504059837 countsByYear W15040598372014 @default.
• W1504059837 countsByYear W15040598372015 @default.
• W1504059837 countsByYear W15040598372016 @default.
• W1504059837 countsByYear W15040598372017 @default.
• W1504059837 countsByYear W15040598372018 @default.
• W1504059837 countsByYear W15040598372019 @default.
• W1504059837 countsByYear W15040598372020 @default.
• W1504059837 countsByYear W15040598372021 @default.
• W1504059837 countsByYear W15040598372022 @default.
• W1504059837 crossrefType "journal-article" @default.
• W1504059837 hasAuthorship W1504059837A5011021512 @default.
• W1504059837 hasAuthorship W1504059837A5012368560 @default.
• W1504059837 hasAuthorship W1504059837A5020043851 @default.
• W1504059837 hasAuthorship W1504059837A5024807342 @default.
• W1504059837 hasAuthorship W1504059837A5026975469 @default.
• W1504059837 hasAuthorship W1504059837A5029825407 @default.
• W1504059837 hasAuthorship W1504059837A5033319328 @default.
• W1504059837 hasAuthorship W1504059837A5038185249 @default.
• W1504059837 hasAuthorship W1504059837A5040155351 @default.
• W1504059837 hasAuthorship W1504059837A5044409463 @default.
• W1504059837 hasAuthorship W1504059837A5045458724 @default.
• W1504059837 hasAuthorship W1504059837A5061427649 @default.
• W1504059837 hasAuthorship W1504059837A5061747115 @default.
• W1504059837 hasAuthorship W1504059837A5065379353 @default.
• W1504059837 hasAuthorship W1504059837A5069747518 @default.
• W1504059837 hasBestOaLocation W15040598372 @default.
• W1504059837 hasConcept C101990758 @default.
• W1504059837 hasConcept C111113717 @default.
• W1504059837 hasConcept C112705442 @default.
• W1504059837 hasConcept C126322002 @default.
• W1504059837 hasConcept C134018914 @default.
• W1504059837 hasConcept C142724271 @default.
• W1504059837 hasConcept C170493617 @default.
• W1504059837 hasConcept C197934379 @default.
• W1504059837 hasConcept C204787440 @default.
• W1504059837 hasConcept C27081682 @default.
• W1504059837 hasConcept C2776033226 @default.
• W1504059837 hasConcept C2776541429 @default.
• W1504059837 hasConcept C2777056448 @default.
• W1504059837 hasConcept C2778375690 @default.
• W1504059837 hasConcept C2780306776 @default.
• W1504059837 hasConcept C673006 @default.
• W1504059837 hasConcept C71924100 @default.

• next